Cadrenal Therapeutics Q4 2023 update: cash $8.5M, tecarfarin expanded to LVADs and APS

Cadrenal Therapeutics, Inc.

Q4 2023 operating expenses (excl. non-cash) totaled $1,160,000; cash used in ops $694,000.
Cash and equivalents at Dec 31, 2023: $8.5 million.
Expanded tecarfarin development to include LVAD and APS patients, addressable market >$2B/yr in US.
Appointed Jeff Cole as COO, overseeing manufacturing, supply chain, IP, and partnering.
Engaged The Sage Group to explore strategic partnerships, co-development, and licensing for tecarfarin.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Cadrenal Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.

Period: the fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 11, 2024, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Cadrenal Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-021251

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.